Dealing with the recent series of allogeneic hematopoietic stem cell transplantation (allo-SCT) performed this decade, we reassessed the clinical impact of pretransplant surgical procedures (SP) for pulmonary lesions of invasive fungal disease (IFD) on subsequent transplant outcome. We focused on the clinical outcomes of seven patients with pulmonary IFD who underwent segmentectomy (n = 4), lobectomy (n = 2) or abscess incision with drainage only (n = 1), and compared results to those of 21 patients carrying pulmonary IFD who never underwent invasive SP before allo-SCT.
| INTRODUC TI ON
Although encouraging survival statistics are now being reported after allo-SCT, pulmonary complications occur in up to half of patients and represent major causes of morbidity and mortality. 1, 2 Infectious processes are a major source of such pulmonary complications, and invasive fungal disease (IFD) may pose a deadly threat to allo-SCT. [3] [4] [5] Some patients may develop pulmonary IFD before transplantation, which could be associated with much more increased treatment-related mortality and subsequent poorer survival, 6, 7 and IFD has thus been considered a relative contraindication to allo-SCT.
However, according to recent advances in diagnostic and therapeutic approaches to pulmonary IFD, 8 an increasing number of patients who have experienced a prior episode of pulmonary IFD eventually undergo allo-SCT. 9, 10 Although no optimal pretransplant strategy for those patients has been firmly established, some patients with nonresolving lesions despite prolonged antifungal treatment or a cavity located near a large vessel may undergo surgical procedures (SP) with the intention of reducing the risk of fungal relapse or massive hemorrhage. 11, 12 Nosari et al 13 reported the feasibility and efficacy of pretransplant SP combined with secondary antifungal prophylaxis in 10 leukemic patients with residual pulmonary IFD before allo-SCT.
Yeghen et al 14 also reported favorable outcomes of SP before bone marrow transplantation, which could prevent subsequent relapse of pulmonary IFD in 100% of cases and had an actuarial survival rate as high as 71% at 2 years. However, these studies were performed more than two decades ago, and the clinical implications might be at variance with those of recent patients under the current antifungal prophylaxis or treatment strategy. This study therefore reassessed the clinical implications of pretransplant SP for patients with pulmonary IFD in an era of growing availability of powerful antifungal agents. Fluconazole or itraconazole was routinely used as the primary IFD prophylaxis and secondary antifungal prophylaxis were decided according to the discretion of transplant physicians. Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score <3 was defined as low, while a score ≥3 was defined as high. 17 Non-relapse mortality (NRM) was defined as death without previous relapse following SCT. Overall survival (OS) was calculated from the date of transplantation to final follow-up or death. GVHD occurring before day 100 after allo-SCT was classified as acute GVHD, whereas that occurring after day 100 after allo-SCT was classified as chronic
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GVHD.
18 Both acute and chronic GVHD were evaluated according to the standard classifications published elsewhere. [19] [20] [21] and the results were compared using Gray's test. The cumulative incidence of IFD was also estimated and compared using Gray's test, considering death without IFD as a competing risk. OS was estimated using the Kaplan-Meier method and was compared using the log-rank test. All statistical tests were two-sided, and values of P < 0.05 were considered statistically significant. All data were analyzed using R version 2.14.0 software (http://www.r-project.org/).
| RE SULTS
| Patient and transplant characteristics
With the detailed review of clinical records from the 484 consecutive patients who underwent allo-SCT over the course of the last decade in our institution, a total of 28 patients (5.8%) were eventually identified as carrying pulmonary IFD before allo-SCT and therefore included in this analysis. Table 1 
| Pre-transplant IFD and SP
Seven patients (25%) underwent SP, at a median 42 days (range, 14-66 days) from diagnosis of IFD, while 21 patients (75%) did not (Table 2 TA B L E 1 Characteristics of patients with pulmonary IFD who did (n = 7) or did not (n = 21) undergo SP before allo-SCT (Table 1) .
Regarding IFD pathogens of 21 patients who did not undergo SP, galactomannan antigen was detected in nine patients but no specific causative organisms were confirmed by sputum culture or BAL/ TBLB, (Table S1 ). (Table 3) .
| IFD recurrence after allo-SCT and risk analysis
| Survivals
Regarding transplant outcomes, OS and cumulative incidence of NRM at 1 year were 53.6% (95% CI, 13.2%-82.5%) and 46.4% (95% TA tool for diagnosing IFD. 22 On the basis of these results, more patients are likely to achieve correct diagnosis after SP (P < 0.001).
| D ISCUSS I ON
Invasive fungal disease recurrence after allo-SCT was observed patients (29%) after allo-SCT. 7 Among the 45 FHCRC patients with IA prior to allo-SCT, 13 had received surgical management and this was not significantly associated with a lower probability of posttransplantion IA. More recently, the MD Anderson Cancer Center also reviewed 29 patients with various hematological malignancies and a history of proven or probable IFD before allo-SCT. 23 Of those, 26 patients (90%) completed more than 4 weeks of antifungal treatment before allo-SCT and five patients (17%) also received SP, but only four patients (14%) eventually developed IFD recurrence after allo-SCT and three patients showed the recurrence at more than 12 months after allo-SCT. 23 These positive data including our results are probably due to current prophylactic strategies with aggressive use of secondary antifungal agents, especially for allo-SCT recipients with proven or probable IFD episodes. In view of the secondary prophylaxis adopted in 21 patients without SP in our series, oral azoles, such as voriconazole (n = 17) or itraconazole (n = 1), were used in a total of 18 patients (81%) and the remaining three patients received intravenous liposomal amphotericin B (n = 2) or micafungin (n = 1) ( Tables 1 and S1 ). These agents have been reported as essentially safe and highly effective for secondary prophylaxis, as they prevented IFD relapse and even improved survival after all-SCT. 5, [24] [25] [26] Although no standardized strategy for secondary antifungal prophylaxis or optimal timing for performing allo-SCT has been defined, a prior episode of IFD might be no longer represent a huge barrier for proceeding to allo-SCT under current options for secondary prophylaxis with new antifungal agents.
Moreover, the use of these new drugs would result in comparable transplant outcomes between patients who did and did not undergo SP, implying that SP before allo-SCT may lack meaning. 27 According to our risk assessment, neither stratified IFD risk scores (P = 0.26) nor SP before allo-SCT (P = 0.69) were associated F I G U R E 1 Cumulative incidence of invasive fungal disease following allo-SCT. The curve indicates the cumulative incidence of IFD over time from the day of stem cell infusion to 1 y after infusion. with IFD recurrence after allo-SCT in an univariate analysis for a total of 28 patients with a prior history of pulmonary IFD (Table 3) This study has several limitations. Because of the retrospective, non-randomized nature, it was subjected to selection bias. In our series, significantly more patients without SP had no CR at allo-SCT, which suggests that these patients were more likely considered ineligible for SP and possibly were more urgently scheduled towards allo-SCT. Moreover, neither matched pair nor multivariate analysis was performed due to the small sample size in our series. Nevertheless, the focus was to outline the clinical implications of pre-transplant SP.
Although further clarification is needed to determine which patients with pulmonary IFD should undergo SP or which antifungal agents to use as secondary prophylaxis, pulmonary IFD is no longer a contraindication for allo-SCT and actively promoting pretransplant SP might not be an appropriate therapeutic strategy.
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